January 25, 2023
(press release)
–
To help hospitals and health systems meet demand during the current surge in respiratory illnesses for fever-reducing products to treat pediatric patients and adults unable to swallow solid oral dosage forms, the Food and Drug Administration Friday released guidance for outsourcing facilities compounding certain ibuprofen oral suspension products. “Although FDA is monitoring the global pharmaceutical supply chain and working, within its authorities, with manufacturers of approved ibuprofen oral suspension products, to bolster supply, temporary flexibility is needed to help ensure that treatment options are available to hospitals and health systems during this period of increased demand,” the guidance states. 
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
